RLAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RLAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2024, Relay Therapeutics received $47.74 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $1.19 Mil on other financial activities. In all, Relay Therapeutics earned $48.92 Mil on financial activities for the three months ended in Mar. 2024.
The historical data trend for Relay Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 5.61 | 426.51 | 388.09 | 289.91 | 34.75 |
Relay Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 1.30 | 2.08 | 9.46 | 21.92 | 48.92 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Relay Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 30.281 | + | 0 | + | 0 | + | 0 | + | 0 | + | 4.472 |
= | 34.75 |
Relay Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:
Cash Flow from Financing | (Q: Mar. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 47.735 | + | 0 | + | 0 | + | 0 | + | 0 | + | 1.187 |
= | 48.92 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $82.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (NAS:RLAY) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Relay Therapeutics's issuance of stock for the three months ended in Mar. 2024 was $47.74 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Relay Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Relay Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Relay Therapeutics received $0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Relay Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Relay Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Relay Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Relay Therapeutics received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Relay Therapeutics's other financing for the three months ended in Mar. 2024 was $1.19 Mil. Relay Therapeutics received $1.19 Mil on other financial activities.
Thank you for viewing the detailed overview of Relay Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Rahmer | officer: See remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Thomas Catinazzo | officer: Vice President, Finance | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Donald A Bergstrom | officer: See Remarks | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Brian Adams | officer: General Counsel | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Sanjiv Patel | director, officer: President and CEO | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Andy Porter | officer: See Remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Mark Murcko | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Sekar Kathiresan | director | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Jami Rubin | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Douglas S Ingram | director | 2525 DUPONT DR, IRVINE CA 92612 |
Third Rock Ventures Gp Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Svf Pauling (cayman) Ltd | 10 percent owner | 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008 |
Picularium, Llc | 10 percent owner | 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036 |
Laura Shawver | director | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
From GuruFocus
By PurpleRose PurpleRose • 08-18-2022
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 02-23-2023
By GuruFocus Research • 11-02-2023
By Value_Insider Value_Insider • 11-07-2022
By GuruFocus Research GuruFocus Editor • 10-14-2022
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 07-28-2022
By Stock market mentor Stock market mentor • 01-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.